Financial Performance - The company's operating revenue for the first half of 2023 was ¥188,245,611.91, representing a 37.62% increase compared to ¥136,781,718.93 in the same period last year[23]. - The net loss attributable to shareholders was ¥48,574,542.40, which is a 26.42% increase in loss compared to ¥38,422,749.52 in the previous year[23]. - The basic and diluted earnings per share were both reported at -¥0.0322, reflecting a 26.27% increase in loss per share compared to -¥0.0255 in the same period last year[23]. - The weighted average return on equity was -2.51%, a decrease of 0.90% compared to -1.61% in the previous year[23]. - The company reported a net loss of CNY 453,261,640.23 in retained earnings as of June 30, 2023, compared to a loss of CNY 404,687,097.83 at the beginning of the year[146]. - The net profit for the first half of 2023 was -40,438,291.02 CNY, compared to -49,730,879.52 CNY in the same period of 2022, showing an improvement of approximately 18.4%[155]. - The total comprehensive income for the period was a loss of ¥47,571,969.38, compared to a profit in the previous period[163]. Cash Flow and Financing - The net cash flow from operating activities improved significantly to ¥1,912,110.43, a 102.88% increase from a negative cash flow of ¥66,375,688.54 in the same period last year[23]. - The company reported a substantial increase in financing activities, with net cash flow from financing activities rising to ¥71,456,932.30, a 1,384.47% increase from a negative cash flow of ¥5,563,136.68[41]. - Cash and cash equivalents at the end of the period reached ¥51,677,517.68, marking a 1,130.03% increase from ¥4,201,327.50 in the previous year[42]. - The company’s cash flow from financing activities generated a net inflow of 71,456,932.30 CNY, compared to a net outflow of -5,563,136.68 CNY in the first half of 2022[159]. - The company received ¥20,000,000.00 from borrowings, down from ¥30,000,000.00 in the previous period, representing a 33.3% decrease[161]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,229,324,242.94, showing a decrease of 1.21% from ¥3,268,933,980.20 at the end of the previous year[23]. - The total liabilities decreased to CNY 1,388,666,964.20 from CNY 1,420,064,960.77, indicating a decline of about 2.2%[146]. - The company's total equity decreased to CNY 1,764,562,664.71 from CNY 1,805,000,955.73, showing a decline in shareholder value[152]. - The company's financial liabilities were reported as zero, indicating no outstanding debts[50]. Operational Highlights - The company faced operational risks and advised investors to be cautious regarding investment risks[4]. - The company has developed 1 dual-patent product and 7 patented products, with 19 domestic invention patents applied and 11 granted, and 6 PCT international invention patents applied[32]. - The "Nongyi Net" e-commerce platform aims to enhance service for agricultural retailers and large growers, utilizing a new retail model that combines online and offline strategies[33]. - The company is entering the ammonia-hydrogen energy sector to address hydrogen storage and transportation challenges, aiming to create a comprehensive logistics system[35]. - The company is focusing on a B2B2C new retail operation model through its professional e-commerce platform, aiming to enhance channel network construction[39]. Market and Strategic Initiatives - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[197]. - A strategic acquisition of a local competitor is anticipated to enhance the company's distribution network and increase market penetration[198]. - The company plans to invest 300 million yuan in R&D for new technologies over the next two years[199]. - New product development includes the launch of two innovative agricultural solutions, expected to contribute an additional 200 million yuan in revenue[200]. Shareholder and Equity Information - A total of 383 employees participated in the employee stock ownership plan, holding 30,595,320 shares, which accounts for 2.03% of the company's total equity[70]. - The total number of restricted shares decreased from 366,847,621 (24.33%) to 334,283,262 (22.17%), a reduction of 32,564,359 shares[125]. - The largest shareholder, Zhang Hangen, holds 28.75% of the shares, totaling 433,423,393 shares[130]. - The report indicates that the company has a significant number of shares held by executives, with specific restrictions on transfer during their tenure[127]. Compliance and Governance - The company has established a risk management framework for its hedging activities, ensuring compliance with relevant laws and regulations[57]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[75]. - The company has no bankruptcy reorganization matters reported during the period[88]. - The company and its controlling shareholders have no records of legal violations or untrustworthiness[91].

独立董事对公司关联方资金占用和对外担保情况的 专项说明和独立意见 根据《在上市公司建立独立董事制度的指导意见》、《上市公司治理准则》、 《江苏辉丰生物农业股份有限公司章程》等的有关规定，我们作为江苏辉丰生物 农业股份有限公司的独立董事，对公司相关事项发表独立意见如下： 一、公司能遵循《公司法》、《证券法》、《关于规范上市公司对外担保行为的 通知》及《关于规范上市公司与关联方资金往来及上市公司对外担保若干问题的 通知》等法律法规和《公司章程》的有关规定，严格控制对外担保风险。 二、我们对报告期内实际控制人及其他关联方占用资金情况进行了核查和监 督，认为报告期内公司不存在控股股东及其他关联方非正常占用公司资金的情况。 三、报告期内公司不存在为控股股东及其他关联方提供担保的情况。 独立董事： 李昌莲、杨兆全、花荣军 二〇二三年八月二十三日 ...

注1：安道麦股份有限公司为本公司重要联营企业安道麦辉丰(江苏)有限公司、安道麦辉丰（上海）农业技术有限公司之控股股东，故将安道麦股份有限公司及其子公司与公司发生的交易作为本公司的其他关联方进行列示 注2：ADAMA KOREA CO.,LTD.同受安道麦股份有限公司控制 法定代表人： 主管会计工作的负责人： 会计机构负责人： 非经营性资金占用及其他关联资金往来情况汇总表 2023半年度 | 编制单位：江苏辉丰生物农业股份有限公司 | | | | | | | | | 单位：人民币元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的 关联关系 | 上市公司核算的 会计科目 | 2023年期初 占用资金余额 | 2023年度占用累计 发生金额 （不含利息） | 2023年度占用资金 的利息 （如有） | 2023年度偿还累计发 生金额 | 2023年期末 占用形成原因 占用资金余额 | 占用性质 | | 控股股东、实际控制人及其附属企业 | | | | | | | | | ...

证券代码：002496 证券简称：辉丰股份 公告编号：2023-028 江苏辉丰生物农业股份有限公司 关于诉讼事项进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 江苏辉丰生物农业股份有限公司（以下简称"公司"）近日收到江苏省盐城市大丰区人 民法院（以下简称"大丰法院"）送达的《民事调解书》，编号（2023）苏 0904 民初 1621 号，主要内容如下： 一、 诉讼事项有关情况 原告：江苏辉丰生物农业股份有限公司 被告：江苏科邦安全技术有限公司、王洪民、刘舜、王平 经法院调解，双方当事人于 2023 年 8 月 21 日自愿达成如下协议： （一）被告江苏科邦安全技术有限公司截止 2023 年 6 月 30 日计欠原告本金 35910800 元，利息 29392584 元(2015 年 5 月 1 日计算至 2023 年 6 月 30 日计 35192584 元，扣除已支 付的 5800000 元),合计 65303384 元。并承付 35910800 元自 2023 年 7 月 1 日至实际履行之 日按月利率 1%计算的利息； （二）被告江苏科邦安 ...

Financial Performance - The company's revenue for Q1 2023 was ¥62,614,374.69, a decrease of 2.33% compared to ¥64,110,688.79 in the same period last year[5] - Net profit attributable to shareholders decreased by 46.33% to ¥10,711,121.07 from ¥19,956,319.79 year-on-year[5] - The company reported a net loss of ¥393,975,976.76 in retained earnings, an improvement from a loss of ¥404,687,097.83 in the previous period[23] - The net profit for Q1 2023 was CNY 8,942,728.42, a decrease of 42.5% compared to CNY 15,503,466.26 in Q1 2022[25] - The total comprehensive income for Q1 2023 was CNY 9,581,345.59, compared to CNY 15,405,002.95 in Q1 2022[25] - The company experienced a decrease in operating profit, which was CNY 6,875,772.38, down from CNY 17,596,515.73 in the previous year[25] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, reaching ¥5,208,302.69, compared to a negative cash flow of ¥28,445,401.98 in the previous year, marking an increase of 118.31%[5] - The cash flow from operating activities showed a net increase of CNY 5,208,302.69, recovering from a net outflow of CNY -28,445,401.98 in Q1 2022[26] - The company's cash and cash equivalents increased to ¥126,727,673.45 from ¥57,971,492.31, representing a growth of 118.00%[22] - The net cash flow from financing activities was CNY 78,117,194.46, a substantial increase from CNY 167,852.96 in Q1 2022[27] Assets and Liabilities - The company's total assets increased by 1.78% to ¥3,327,257,957.69 from ¥3,268,933,980.20 at the end of the previous year[5] - Total liabilities as of Q1 2023 were ¥1,469,726,191.57, an increase from ¥1,420,064,960.77 at the beginning of the year[22] - Current assets totaled ¥584,344,900.39, up 7.66% from ¥542,615,284.11 at the beginning of the year[22] Shareholder Information - The actual controller of the company, Mr. Zhong Hangen, holds 433,423,393 shares, accounting for 28.75% of the total share capital[19] - The top ten shareholders include Mr. Zhong Hangen, who has a shareholding of 28.75%, followed by Su Shi with 4.94% and Zhang Hongde with 4.82%[19] - The top ten shareholders hold a total of 103,399,053 unrestricted shares[12] - The company has a total of 39,696 common shareholders at the end of the reporting period[19] Research and Development - Research and development expenses decreased by 45.89% to ¥436,130.12 from ¥806,079.42 year-on-year, indicating reduced investment in R&D[9] - The company's research and development expenses for Q1 2023 were ¥436,130.12, a decrease of 46.10% from ¥806,079.42 in the previous period[24] Investment and Income - Investment income fell by 34.40% to ¥13,480,288.47 from ¥20,550,533.29, primarily due to decreased returns from equity method investments[9] - The company's net investment income for Q1 2023 was ¥13,480,288.47, a decrease of 34.38% compared to ¥20,550,533.29 in the previous period[24] Legal and Compliance - The company is involved in ongoing litigation regarding unpaid rental obligations, with a case filed on March 8, 2023[14] - The company has made provisions for impairment related to the dismantling of production lines and facilities due to safety and environmental regulations[16] Equity and Ownership Plans - The total equity attributable to shareholders increased slightly by 0.53% to ¥1,969,094,967.61 from ¥1,958,663,035.81 at the end of the previous year[5] - The company has a first-phase employee stock ownership plan with 12,606,576 shares[19] Other Information - The company completed the transfer of 51% equity in Andermatt Huifeng for a total consideration of RMB 663.35 million, with a remaining deferred payment of RMB 259.86 million[13] - The company has not disclosed any new developments regarding significant commitments or other important matters as of the report date[17]

Financial Performance - The company's operating revenue for 2022 was ¥267,535,512.07, a decrease of 75.58% compared to ¥1,095,481,169.58 in 2021[24]. - The net profit attributable to shareholders was -¥454,951,605.22, representing a decline of 247.84% from ¥307,740,641.70 in the previous year[24]. - The cash flow from operating activities showed a net outflow of -¥36,774,850.90, a decrease of 149.53% compared to a positive cash flow of ¥74,254,869.02 in 2021[24]. - The basic and diluted earnings per share were both -¥0.30, down 250.00% from ¥0.20 in 2021[24]. - Total assets at the end of 2022 were ¥3,268,933,980.20, a decrease of 13.15% from ¥3,764,024,801.92 at the end of 2021[24]. - The net assets attributable to shareholders decreased by 18.79% to ¥1,958,663,035.81 from ¥2,411,882,951.96 in 2021[24]. - The company reported a significant loss from fair value changes of financial assets amounting to -¥39,168,793.71 in 2022[32]. - The total non-recurring losses amounted to -¥141,303,257.21, compared to a gain of ¥642,139,790.78 in 2021[32]. - The company reported a substantial loss of 217,326,147.78 CNY due to the impairment of receivables from a subsidiary, with 106,011,694.89 CNY allocated to the profit attributable to the parent company's owners[34]. - The company reported a net profit of -¥373,507,047.48 in 2022, a significant decline from a profit of ¥203,048,220.29 in 2021[74]. Business Transformation and Strategy - The company underwent a business transformation in 2021, shifting its main operations from pesticide production and sales to the research and development of pesticide formulations, brand operation, agricultural e-commerce, and petrochemical supply chain[23]. - The company aims to transform into a leader in the agricultural e-commerce sector through the development of 288 segments and a focus on end-user services[49]. - The company is focusing on the development of new biological agricultural products, including bio-pesticides and bio-fertilizers, to meet market demand and enhance competitiveness[92]. - The company has outlined its 2023 operational strategy, emphasizing quality improvement and the establishment of a comprehensive agricultural service platform[94]. - The company plans to focus on the "Two Increases and Two Goods" strategy in its functional agriculture division, aiming to enhance production and income while ensuring product quality[93]. Research and Development - The company has applied for 19 domestic invention patents in the field of biostimulants, with 11 granted and 6 PCT international patents applied for, including one awarded in Australia[46]. - The company has invested ¥500 million in the petrochemical warehousing and logistics project, which spans 390 acres and has a total storage capacity of 308,000 cubic meters[50]. - The company reported a significant reduction in R&D expenses, which fell by 92.69% from CNY 28,867,114.55 in 2021 to CNY 2,110,866.41 in 2022[66]. - The number of R&D personnel decreased by 73.33% from 30 in 2021 to 8 in 2022, with R&D personnel now accounting for 26.67% of the workforce[68]. - R&D investment decreased significantly to ¥2,913,405.89 in 2022 from ¥45,388,085.70 in 2021, a decline of 93.58%[69]. Market and Industry Trends - The agricultural market in China maintained a steady growth trend in 2022, despite challenges from the Russia-Ukraine conflict, with significant fluctuations in raw material prices[38]. - Over 50% of pesticide varieties experienced a year-on-year price decline of 20% to 30%, with some products dropping by as much as 50%[40]. - The agricultural industry is expected to benefit from favorable government policies and the "14th Five-Year" national pesticide industry development plan, enhancing the industry's support for agricultural production[39]. - The company is focusing on the development of biostimulants, which are expected to play a significant role in increasing crop yields and maintaining agricultural ecological balance[41]. Governance and Compliance - The company maintains complete independence from its controlling shareholders in terms of business, assets, personnel, and finance, with no shared assets or financial dependencies[102][103][104][105]. - The company has established an independent financial accounting department and a separate accounting system, ensuring independent financial decision-making[105]. - The company has a robust governance structure that complies with the Company Law and relevant regulations, with no significant discrepancies noted[101]. - The company has established a comprehensive internal control system that is effective and suitable for its operations[141]. - The internal control audit report received a clean opinion with an emphasis on certain matters[146]. Legal and Regulatory Issues - The company has faced challenges in managing its subsidiary, Shijiazhuang Ruikai Chemical Co., Ltd., due to unresolved disputes since November 1, 2020, affecting its operational control[153]. - The company is involved in multiple lawsuits with a total amount of approximately 87.71 million yuan (8,771,000 yuan) pending in various stages of litigation[179]. - The company has recognized a provision for estimated liabilities amounting to approximately 2.8 million yuan (280,000 yuan) related to ongoing litigation[180]. - The company has faced a total of 318 labor-related disputes, with 1,145.52 thousand yuan (1,145,520 yuan) in estimated liabilities recognized[180]. Shareholder and Dividend Policies - The profit distribution policy stipulates that at least 10% of the distributable profit should be allocated to shareholders annually, ensuring a stable and continuous distribution approach[133]. - The company prioritizes cash dividends, with a requirement that the cash distributed should not be less than 10% of the current year's distributable profit[133]. - The company did not propose any cash dividend distribution for the reporting period, despite having positive distributable profits[137]. - The company has established a shareholder return plan to enhance the transparency of cash dividends and meet investor expectations[133]. Future Outlook - Future outlook indicates a focus on expanding market presence and enhancing product offerings, with plans to invest in new technologies and product development[110]. - Jiangsu Huifeng aims to enhance its research and development capabilities, particularly in the agricultural biotechnology sector, to support long-term growth[110]. - The company anticipates a continued upward trend in revenue growth, projecting a target of 66.41% increase in the upcoming fiscal year[109]. - Jiangsu Huifeng plans to leverage digital marketing strategies to enhance customer engagement and drive sales growth[110].

出席本次业绩说明会的人员有：总经理张晓波先生，公司副董事长、副总经理裴 柏平先生，董事、副总经理兼财务负责人周京先生，副总经理兼董事会秘书孙永良先 生，独立董事杨兆全先生。 欢迎广大投资者积极参与，特此公告 。 江苏辉丰生物农业股份有限公司董事会 证券代码：002496 证券简称：辉丰股份 公告编号：2023-018 江苏辉丰生物农业股份有限公司 关于举行2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 江苏辉丰生物农业股份有限公司（以下简称"公司"）第八届董事会第二十三次 会议审议通过了《2022年年度报告及其摘要》，相关公告已于2023年4月28日刊登于巨 潮资讯网（www.cninfo.com.cn）及《证券时报》、《中国证券报》，敬请投资者查阅。 公司将于2023年5月12日（星期五）15:00～17:00 通过全景网提供的网上平台举 办2022年度业绩说明会，本次年度业绩说明会将采用网络远程的方式举行，投资者可 登陆"全景•路演天下"（http://rs.p5w.net）参与本次年度业绩说明会。 二○二三年四月二十六日 ...

江苏辉丰生物农业股份有限公司 证券代码：002496 证券简称：辉丰股份 江苏辉丰生物农业股份有限公司投资者关系活动记录表 编号：2017-001 | --- | --- | --- | |----------------|------------------|---------------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 □媒体采访 | | 投资者关系活动 | □ 业绩说明会 | □新闻发布会 □路演活动 | | 类别 | □现场参观 | □其他 （请文字说明其他活动内容） | | | | 长江证券：马太、鞠龙 | | 参与单位名称 | | 天风证券：吴頔 申万宏源：陈俊杰 | | 及人员姓名 | | 工银瑞信：高京霞 嘉实基金：付赫 华夏基金：杨晋、蒋文超 | | | 兴银基金：蔡国亮 | | | 时 间 | 2017.10.27 | | | | | | | 地 点 | 公司会议室 | | | 接待人员姓名 | | 董事长：仲汉根 董事会秘书：孙永良 | | 投资者关系活动 | 1 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥66,265,164.41, representing a decrease of 58.30% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥27,839,725.19, which is a 264.79% increase in loss compared to the previous year[5]. - The basic earnings per share were -¥0.0185, reflecting a 264.79% increase in loss compared to -¥0.0120 in the same period last year[5]. - The company recorded a loss of ¥41,400,260.42 after deducting non-recurring gains and losses, which is a 40.18% increase in loss compared to the previous year[5]. - The net profit for Q3 2022 was -94,287,267.67 CNY, a significant decline compared to a net profit of 504,574,026.34 CNY in the same period last year[30]. - Operating profit for Q3 2022 was -88,753,084.14 CNY, down from 586,627,873.49 CNY in Q3 2021[30]. - The company reported a total comprehensive income of -92,899,627.44 CNY for Q3 2022, compared to 306,092,720.32 CNY in Q3 2021[31]. - The basic and diluted earnings per share for Q3 2022 were both -0.0440 CNY, down from 0.3558 CNY in the previous year[31]. Revenue and Costs - The company reported a significant decrease in operating income, down 79% year-on-year to ¥203,046,883.34, primarily due to a reduction in the production and sales of original medicines and formulations following a major asset restructuring in May 2021[11]. - Total operating revenue for the period was CNY 203,046,883.34, a significant decrease from CNY 958,363,096.96 in the previous period, representing a decline of approximately 78.8%[29]. - Total operating costs amounted to CNY 278,430,091.62, down from CNY 1,086,940,213.94 in the previous period, indicating a reduction of about 74.3%[29]. Cash Flow and Assets - The net cash flow from operating activities was -¥13,280,280.62, indicating a 60.85% improvement compared to -¥19,846,276.53 in the previous year[5]. - The net cash flow from operating activities was negative at RMB -13,280,280.62, a 61% decline compared to RMB -8,256,295.75, driven by increased prepayment expenditures in trade business[12]. - The net cash flow from investing activities decreased by 82% to RMB 93,380,418.23 from RMB 509,605,414.32, primarily due to the receipt of equity transfer payments in the previous year[12]. - The net cash flow from financing activities improved by 95% to RMB -40,383,881.24 from RMB -760,298,853.54, as the company repaid bank loans and non-related party borrowings in the prior period[12]. - The company's cash and cash equivalents increased to CNY 194,693,419.11 from CNY 155,665,836.67, reflecting a growth of approximately 25%[25]. - Cash and cash equivalents at the end of Q3 2022 totaled 133,302,694.68 CNY, an increase from 78,729,166.42 CNY at the end of Q3 2021[33]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,675,746,320.73, a decrease of 2.35% from the previous year[5]. - Total assets as of September 30, 2022, were CNY 3,675,746,320.73, down from CNY 3,764,024,801.92 at the beginning of the year, indicating a decrease of about 2.4%[27]. - Total liabilities increased slightly to CNY 1,546,597,917.93 from CNY 1,543,377,061.48, reflecting a marginal increase of about 0.1%[27]. - The company's equity attributable to shareholders decreased to CNY 2,348,410,977.42 from CNY 2,411,882,951.96, a decline of approximately 2.6%[27]. - The company’s non-current assets totaled CNY 2,886,901,471.11, down from CNY 2,996,051,127.12, indicating a decrease of about 3.7%[26]. - The company’s total current liabilities increased to CNY 1,238,486,087.63 from CNY 1,204,148,121.23, representing an increase of approximately 2.8%[27]. Expenses - Management expenses decreased by 61% to RMB 92,861,875.40 from RMB 241,161,139.35, primarily due to the reduction in pharmaceutical and formulation production and sales following a major asset restructuring completed in May 2021[12]. - R&D expenses plummeted by 92% to RMB 1,569,090.22 from RMB 20,833,795.06, attributed to decreased investment in pharmaceutical R&D after the asset restructuring[12]. - The company incurred financial expenses of 17,478,131.99 CNY in Q3 2022, compared to 13,819,607.29 CNY in the same period last year[30]. - The total investment income for Q3 2022 was 13,722,037.41 CNY, a decrease from 703,680,377.78 CNY in Q3 2021[30]. Shareholder Information - As of the end of the reporting period, the total number of ordinary shareholders was 44,445, with the largest shareholder, Zhang Hangen, holding 31.19% of the shares[14]. Legal and Regulatory Issues - The company is facing ongoing litigation related to asset disposals and shareholder agreements, with significant financial implications pending resolution[17][18].